SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-22-002076
Filing Date
2022-06-23
Accepted
2022-06-23 15:40:54
Documents
4

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO THE SCHEDULE 13D sc13da111375004_06232022.htm SC 13D/A 342187
2 PRESS RELEASE ex991to13da111375004_062322.htm EX-99.1 39697
3 JOINT FILING AND SOLICITATION AGREEMENT ex992to13da111375004_062322.htm EX-99.2 24429
4 POWERS OF ATTORNEY ex993to13da111375004_062322.htm EX-99.3 35748
  Complete submission text file 0000921895-22-002076.txt   443777
Mailing Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653
Business Address 23046 AVENIDA DE LA CARLOTA, SUITE 600 LAGUNA HILLS CA 92653 (917) 595.2850
PharmaCyte Biotech, Inc. (Subject) CIK: 0001157075 (see all company filings)

IRS No.: 621772151 | State of Incorp.: NV | Fiscal Year End: 0430
Type: SC 13D/A | Act: 34 | File No.: 005-91495 | Film No.: 221035319
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 641 LEXINGTON AVENUE 26TH FLOOR NEW YORK, NY 10022
Business Address 641 LEXINGTON AVENUE 26TH FLOOR NEW YORK, NY 10022 212.974.3070
Iroquois Capital Management, LLC (Filed by) CIK: 0001481867 (see all company filings)

IRS No.: 010786483 | State of Incorp.: DE
Type: SC 13D/A